bottom line us pharma earn got shaki start last week
sell earn drag
group increas us price pressur key product
 xarelto eliqui humira currenc headwind ex-u
issu pressur three compani report last
week also set cautiou outlook three
report week look thing glass half full
expect group lower suggest in-line
earn guidanc reason well receiv
note present updat model base
analysi latest prescript price trend expect
three compani report solid number appear best posit
three deliv quarterli beat given still gener restasi
market investor convers surprisingli light agn
recent week even stock ytd detail
guidanc updat key pipelin asset like
drive stock reaction one somewhat
concern ep guidanc estim ep
given impact lyrica patent loss currenc
headwind consensu emerg new product stori
may help overcom weak around earn
investor look return growth abl deliv
beyond also get first-tim guidanc along
result keytruda gardasil drive stori
look greater insight long-term growth driver
busi develop prioriti call maintain rate
target price three compani head earn
suiss seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis
pressur us major pharma compani provid guidanc
yoy chang trade weight dollar index major currenc index
board governor feder reserv system us trade weight dollar index major currenc dtwexm retriev fred feder reserv bank st loui
trade weight major currenc index base exchang rate us dollar basket major currenc includ euro area canada japan unit kingdom
switzerland australia sweden
charl martineau univers toronto figur currenc revers cours estim fx headwind
yoy chang trade weight dollar index major currenc index
figur sequenti usd expect modestli stronger
qoq chang trade weight dollar index major currenc index
price month
watch
passcod sale cs
concern go whether manag would abl
maintain guidanc call perform net incom per
share pnip growth compar follow unexpect
fda approv gener canasa suspens agn textur
breast implant product eu although manag earli januari
reiter commit current consensu pnip vs
yet caught credibl commit
remain question investor given competit inject cgrp
botox therapeut potenti entri new toxin pressur botox
aesthet revis pnip estim
maintain pnip estim
risk call includ greater-than-expect competit
botox linzess disappoint pipelin data especi rapastinel
notabl model updat lower sale forecast
restasi modestli consensu
howev maintain sale estim botox vs
consensu linzess vs consensu vraylar
earn look commentari propos sale
women infecti diseas busi impact far
potenti impact recent multipl anti-cgrp product launch
botox migrain guidanc gener competit restasi
delzicol progress pipelin product notabl rapastinel
depress oral cgrp migrain
 close
valuat metric
number share
allergan global brand pharmaceut compani develop
commerci product focus seven key therapeut
urolog anti-infect
profit tax
chang work capit
flow oper
free cash-flow firm
flow invest
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
blue sky valuat base greater sale botox
viberzi oral cgrp compar current base case
assumpt also model higher gross margin oper
margin base case assumpt blue sky valuat
base dcf driven wacc termin valu
grey sky valuat base lower sale key
market product botox restasi gi
franchis oral cgrp compar current base case
assumpt also model lower gross margin oper
margin base case assumpt grey sky valuat
base dcf driven wacc termin valu
 close
charl martineau univers toronto figur cs estim agn metric
price month
watch
password fourth quarter earn
first-tim guidanc key focu believ current
consensu may yet adjust fx incom line
expect near zero vs consensu thu
believ current consensu may need downward revis top
bottom line expect vs consensu revenu
vs consensu ep furthermor light
recent propos bristol/celgen mega-merg believ investor
like want better understand new ceo strateg outlook
compani particularli respect scope busi develop
near-term revenu trend key product ibranc xeljanz
xtandi posit compani look toward time
period pipelin emerg return compani growth
maintain ep revis ep
estim main risk call
surprisingli posit neg data product upcom data
readout tanezumab bavencio greater/wors commerci
execut key market product
notabl model updat lower ww sale ibranc
vs consensu rais ww sale
xeljanz consensu maintain
ww prevnar forecast vs consensu
earn look commentari expect question
earn call focus busi develop prioriti
new ceo board along detail current growth driver
ibranc xeljanz xtandi etc potenti pipelin program
tafamidi tanezumab product emerg potenti help
 close
valuat metric
number share
pfizer inc biopharmaceut compani engag
discoveri develop manufactur sale medicin
peopl anim world-wide
profit tax
chang work capit
flow oper
free cash-flow firm
flow invest
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
blue sky valuat base greater sale
ibranc prevnar xtandi bavencio compar current base
case assumpt also model higher oper margin
base case assumpt blue sky valuat base dcf
driven wacc termin valu
grey sky valuat base lower sale ibranc
prevnar xtandi bavencio compar current base case
assumpt also model lower oper margin
base case assumpt grey sky valuat base dcf
driven wacc termin valu
 close
charl martineau univers toronto figur cs estim metric
price month
watch
passcod sale cs
remain key driver cs estim keytruda sale
us global vs consensu
respect focu nsclc opportun also expect
greater attent opportun deliv upsid especi outsid
us also look insight merck busi develop
prioriti might look use larg cash reserv
find right asset boost pipelin maintain
target price outperform rate revis ep
estim risk includ
slower expect uptak keytruda gardasil disappoint
progress pipelin asset busi develop effort diversifi
portfolio
notabl model updat quarter lower us keytruda sale
estim slightli estim line recent iqvia
symphoni sale trend rais estim gardasil
consensu slightli lower janumet sale
consensu given recent price/volum trend
nsclc
earn look commentari keytruda uptak
expect addit keytruda
monotherapi combin therapi data lung cancer renal cell
carcinoma indic uptak gardasil us
outsid us notabl china merck busi develop
prioriti help diversifi compani
 close
valuat metric
number share
merck co inc global health care compani deliv health
solut prescript medicin market
joint ventur oper segment
anim health consum allianc
profit tax
chang work capit
flow oper
free cash-flow firm
flow invest
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
blue sky valuat base greater sale
keytruda januvia gardasil compar current base case
assumpt also model higher gross margin oper
margin base case assumpt blue sky valuat
base dcf driven wacc termin valu
grey sky valuat base lower sale
keytruda januvia gardasil compar current base case
assumpt also model lower gross margin oper
margin base assumpt grey sky valuat base
dcf driven wacc termin valu
 close
charl martineau univers toronto figur cs estim metric
sale
research develop
sell gener administr
incom incom tax non-controlling
net incom continu oper
provis incom tax
incom discontinu oper net tax
incom loss attribut non-controlling interest
net incom attribut sharehold
weight average share calcul dilut ep
 includ mileston sale
revenu
total incom expens
provis incom tax
revenu
amort intang
equiti incom affili
total incom expens
provis incom tax
compani mention price
